Thursday 19 Nov 2026 Abu Dhabi UAE
Prayer Timing
Today's Edition
Today's Edition
UAE

Medical guidance key to the safe use of GLP-1 weight-loss drugs: doctors

Medical guidance key to the safe use of GLP-1 weight-loss drugs: doctors (ILLUSTRATIVE IMAGE)
19 Nov 2026 19:27

SAMIHAH ZAMAN (ABU DHABI)

Weight-loss drugs are all the rage globally, with the medications enabling patients to transform their lifestyles. Initially developed to treat chronic conditions like diabetes, the class of medication – specifically glucagon-like peptide -1 receptor agonists (GLP-1 RA) – is now approved for the treatment of obesity and its comorbidities.

Widely available across the globe in both injectable and oral forms, the medicines have become the go-to for many patients struggling with excess weight. For their own safety, doctors have however cautioned people to consult a physician first, and to stick to prescribed treatment regimens.

The caution follows recent mandates by the US Food and Drug Administration (FDA) for GLP-1 manufacturers to add information on medication labels about the increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of these medicines. The safety communication was issued on November 9, and it calls on the makers of all popular weight loss drugs – Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo and others – to specify the increased risk to users of developing acute, painless, decreased vision in one eye, or even permanent vision loss.

Speaking to Aletihad, doctors in the UAE advised the use of GLP-1 drugs only under medical supervision.

“GLP-1 medications have significantly changed the way we manage obesity. We are seeing meaningful, sustained weight loss; improvements in blood sugar, blood pressure, and other obesity-related complications; and, importantly, better quality of life,” said Dr Noor Naji, Head of Department and Consultant Internal Medicine at Burjeel Medical City.

“My main concern [however] is the unsupervised use of these medications. They are prescription medicines, not cosmetic weight-loss medications, and they are not suitable for everyone. Patients need proper assessment, appropriate dosing, and follow-up to identify side effects and monitor their health,” she added.

Dr Saad Kamil, Specialist Family Medicine at Medeor Hospital, Abu Dhabi, said some GLP-1 medications could also prove harmful for certain patients, and should only be taken under a doctor’s care.

“While generally well tolerated when appropriately prescribed, they can be associated with important complications, including pancreatitis, gallstones or gallbladder inflammation, delayed gastric emptying, and, in some patients with diabetes, worsening of existing diabetic retinopathy. Patients should [also] seek medical attention for warning symptoms such as severe persistent abdominal pain or significant visual changes,” he said, urging patients not to start or adjust the use of weight-loss treatment without consulting a doctor.

In the absence of medical advice, people may also find that they do not respond to GLP-1 medications, said Dr Lamya Kamal, Consultant Family Medicine and Lifestyle Medicine at Durraiya Kamal Medical Clinic.

“It seems like right now, everyone is thinking about [GLP-1 drugs], or has heard about it or knows someone who's taking it. [But] there are side effects and contraindications, and there are some people that they will not respond to GLP-1s. That is why having a consultation is really important,” she said.

Widespread Benefits from Guided Use
Despite the caution, Dr Kamal explained that the increased risk of developing NAION from taking GLP-1 medications is minimal at best: about 2.6 additional cases per 100,000 people per year.

GLP-1 medicines can meanwhile present a slew of benefits for eligible patients, including for people battling obesity, type 2 diabetes, cardiovascular disease, insulin resistance, metabolic syndrome, hypertension, fatty liver disease, and sleep apnoea.

The medications can also help patients regain control over hunger, reduce food cravings, and adopt healthier habits.

“When combined with proper medical supervision, nutrition, and lifestyle changes, they can make a real difference to long-term health,” Dr Naji said.

Eligibility
Under current guidelines, GLP-1 drugs are recommended for adults with a body mass index (BMI) of 30 kg/m² or higher, or a BMI of 27 alongside weight-related medical conditions like type 2 diabetes, hypertension, or sleep apnoea.

In most cases, patients are able to lose 15 to 20 per cent of their body mass while taking the medications.

But if the treatment is not combined with lifestyle changes – including a shift to healthier nutrition habits and regular physical activity - weight gain is common once their use is halted.

“Weight regain can occur after treatment is stopped, particularly if lifestyle changes are not maintained. Obesity is a chronic medical condition, so we approach GLP-1 treatment as part of a long-term weight-management strategy,” Dr Naji said.

Dr Kamal added that the drugs should not be viewed as a “fast-track” method for losing weight: “These are incredible drugs for people with insulin resistance, metabolic syndrome and type 2 diabetes who otherwise may not have had the health benefits that they can now.”

Copyrights reserved to Aletihad News Center © 2026